149 related articles for article (PubMed ID: 2477560)
1. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Goldrath DE; Messing EM
J Urol; 1989 Oct; 142(4):1082-4. PubMed ID: 2477560
[TBL] [Abstract][Full Text] [Related]
2. The value of serum prostate specific antigen determinations before and after radical prostatectomy.
Lange PH; Ercole CJ; Lightner DJ; Fraley EE; Vessella R
J Urol; 1989 Apr; 141(4):873-9. PubMed ID: 2467013
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
GarcĂa-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications.
Epstein JI; Eggleston JC
Hum Pathol; 1984 Sep; 15(9):853-9. PubMed ID: 6381284
[TBL] [Abstract][Full Text] [Related]
6. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
Safa AA; Reese DM; Carter DM; Phillipson J; Smith R; Dougherty S
Am J Clin Oncol; 1998 Aug; 21(4):323-6. PubMed ID: 9708626
[TBL] [Abstract][Full Text] [Related]
7. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy.
Ferguson JK; Oesterling JE
Urol Clin North Am; 1994 Nov; 21(4):677-85. PubMed ID: 7526514
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
10. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC
J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037
[TBL] [Abstract][Full Text] [Related]
12. The value of prostate-specific antigen in the management of localized prostatic cancer.
Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
[TBL] [Abstract][Full Text] [Related]
13. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
14. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
[TBL] [Abstract][Full Text] [Related]
16. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.
Terris MK; Klonecke AS; McDougall IR; Stamey TA
J Nucl Med; 1991 Sep; 32(9):1713-7. PubMed ID: 1715394
[TBL] [Abstract][Full Text] [Related]
17. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of prostate specific antigen in patients with prostate cancer.
Hudson MA; Bahnson RR; Catalona WJ
J Urol; 1989 Oct; 142(4):1011-7. PubMed ID: 2477559
[TBL] [Abstract][Full Text] [Related]
19. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
Theodorescu D; Frierson HF; Sikes RA
J Urol; 1999 May; 161(5):1442-8. PubMed ID: 10210369
[TBL] [Abstract][Full Text] [Related]
20. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]